Efficacy and toxicity of capecitabine combined with intensitymodulated radiotherapy after D1/D2 lymph node dissection in patients with gastric cancer  

作　　者：Xin Wang Wei-Hu Wang Shu-Lian Wang Yong-Wen Song Yue-Ping Liu Yuan Tang Ning Li Wen-Yang Liu Hui Fang Ye-Xiong Li Dong-Bing Zhao Yihebali Chi Lin Yang Jing Jin 

机构地区：[1]Department of Radiation Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China [2]Department of Radiation Oncology,Peking University Cancer Hospital and Institute,Beijing 100001,China [3]Department of Radiation Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital&Shenzhen Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Shenzhen 518116,Guangdong Province,China [4]Department of Pancreatic and Gastric Surgery,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China [5]Department of Medical Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China

出　　处：《World Journal of Gastrointestinal Oncology》2021年第10期1532-1543,共12页世界胃肠肿瘤学杂志（英文版）（电子版）

基　　金：the Independent Ethics Committees of Cancer Institute and Hospital,Chinese Academy of Medical Sciences(Approved No.11-72/507).

摘　　要：BACKGROUND Adjuvant chemoradiotherapy(ACRT)with oral capecitabine and intensitymodulated radiotherapy(IMRT)were well tolerated in a phase I study in patients who had undergone partial or total gastrectomy for locally advanced gastric cancer(GC).This phase II study aimed to further determine the efficacy and toxicity of this combination after radical resection and D1/D2 lymph node dissection(LND)for patients with locally advanced GC.AIM To further determine the efficacy and toxicity of this combination after radical resection and D1/D2 LND for patients with locally advanced GC.METHODS Forty patients(median age,53 years;range,24-71 years)with pathologically confirmed adenocarcinoma who underwent D1/D2 LND were included in this study.The patients received ACRT comprising IMRT(total irradiation dose:45 Gy delivered in daily 1.8-Gy fractions on 5 d a week over 5 wk)and capecitabine chemotherapy(dose:800 mg/m²twice daily throughout the duration of radiotherapy).The primary study endpoint was disease-free survival(DFS),and the secondary endpoints were overall survival(OS),toxic effects,and treatment compliance.RESULTS The 3-year DFS and OS were 66.2%and 75%,respectively.The median time to recurrence was 19.5 mo(range,6.1-68 mo).Peritoneal implantation(n=10)was the most common recurrence pattern,and the lung was the most common site of extra-abdominal metastases(n=5).Nine patients developed grade 3 or 4 toxicities during ACRT.Two patients discontinued ACRT,while eleven underwent ACRT without receiving the entire course of capecitabine.There were no treatmentrelated deaths.CONCLUSION The ACRT protocol described herein showed acceptable safety and efficacy for patients with locally advanced GC who received radical gastrectomy and D1/2 LND.

关 键 词：Gastric cancer RADIOTHERAPY CHEMORADIOTHERAPY Clinical trial Phase II 

分 类 号：R735.2[医药卫生—肿瘤]